All News
Filter News
Found 140 articles
-
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference
8/31/2022
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 3:30 p.m. ET.
-
Lytix Biopharma: Second quarter and first half of 2022 results
8/25/2022
Lytix Biopharma, a Norwegian immune-oncology company, releases its second quarter and first half 2022 results - New encouraging clinical data.
-
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
8/11/2022
Verrica Pharmaceuticals Inc. today announced financial results for the second quarter ended June 30, 2022.
-
Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan
8/1/2022
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Torii Pharmaceutical Co., Ltd. (“Torii”) dosed the first patient in its Phase 3 trial of VP-102.
-
Warts Treatment Market: Expected Development on the basis of Study of Key Players Research, Growth Predictions and Forecast 2030
7/29/2022
Forecast to 2030,’ thoroughly examines the Warts Treatment industry to provide essential data & information for the targeted readers.
-
Verrica Announces Pricing of Public Offering of Common Stock - June 30, 2022
6/30/2022
Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced the pricing of its underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $2.10 per share.
-
Verrica Pharmaceuticals Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum
6/28/2022
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company held a Type A meeting with the U.S. Food and Drug Administration (FDA) on June 27, 2022 regarding the path forward for the resubmission and potential approval of the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum.
-
In the third and most recent FDA letter, Verrica noted that none of the issues were specific to VP-102 and how it is manufactured.
-
Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC
5/24/2022
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum).
-
The FDA has a few target action dates for the end of the month, although PDUFA dates can sometimes seem like a moving target.
-
Lytix Biopharma - Invitation to Capital Markets Day in Oslo, June 1, 2022
5/19/2022
The CMD is a live event, open for physical attendance at Hotel Continental in Oslo, Norway, as well as a live webcast.
-
Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results
5/9/2022
Verrica Pharmaceuticals Inc. today announced financial results for the first quarter ended March 31, 2022.
-
Lytix Biopharma to host Capital Markets Day - June 1, 2022
5/3/2022
Lytix Biopharma is pleased to announce that it will host a Capital Markets Day for investors, analysts and media on Wednesday, June 1, 2022
-
Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
4/7/2022
Verrica Pharmaceuticals Inc. today announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022 at 3:00 p.m. ET.
-
Lytix Biopharma receives milestone payment from Verrica Pharmaceuticals Inc. triggered by first patient dosed with LTX-315
4/5/2022
Lytix Biopharma AS notes that the first patient has been dosed in Verrica Pharmaceuticals Inc.'s Phase II study evaluating LTX-315 for the treatment of basal cell carcinoma (skin cancer).
-
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
4/5/2022
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases re
-
Growing Prevalence of HPV Infections Driving Growth in Warts Therapeutics Market from 2020 to 2030: Says TMR
3/3/2022
Growing awareness regarding warts and their treatment is helping the global warts therapeutics market take on a high growth curve.
-
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results
3/2/2022
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2021.
-
Verrica Pharmaceuticals Announces Participation in the 42nd Annual Cowen Virtual Healthcare Conference
2/24/2022
Verrica Pharmaceuticals Inc. announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the 42nd Annual Cowen Virtual Healthcare Conference on Wednesday, March 9, 2022, at 11:10 a.m. ET.
-
XyloCor Therapeutics Expands Leadership Team with Accomplished Pharmaceutical Executives to Accelerate Clinical Development Programs and Drive Corporate Growth
1/18/2022
XyloCor Therapeutics today announced that it has appointed Elizabeth Tarka, M.D. as Chief Medical Officer and A. Brian Davis as Chief Financial Officer.